Skip to main content

Shark Cartilage Extract

Scientific Name(s): Sphyrna lewini (Hammerhead Shark), Squalus acanthias (spiny dogfish shark)
Common Name(s): Hammerhead shark, Matrix metalloproteinase inhibitors, Shark cartilage, Spiny dogfish shark

Medically reviewed by Drugs.com. Last updated on Jul 20, 2022.

Clinical Overview

Use

Shark cartilage has been investigated for use in treating cancer; however, clinical data is lacking to support a place in therapy. A role in the management of psoriasis and other inflammatory conditions such as rheumatoid arthritis has been suggested.

Dosing

Commercial doses range from 0.5 to 4.5 g/day, given in 2 to 6 divided doses. Oral shark cartilage preparations should be taken on an empty stomach, and acidic fruit juices should be avoided for 15 to 30 minutes before and after administration. Topical preparations containing shark cartilage 5% to 30% are also available.

Contraindications

Use with caution, if at all, in patients with coronary artery disease and peripheral artery disease because of the antiangiogenic effects of shark cartilage. Due to concerns regarding hypercalcemia, use caution in patients with renal disease, cardiac arrhythmias, or cancer; monitoring is recommended.

Pregnancy/Lactation

Avoid use. Information regarding safety and efficacy in pregnancy and lactation is lacking.

Interactions

Coadministration of shark cartilage with other drugs (eg, calcium supplements, thiazide diuretics) may increase calcium levels.

Adverse Reactions

The most commonly reported adverse effects are mild to moderate and include GI distress, nausea, and taste alterations. Cases of allergic occupational asthma from shark cartilage dust have been reported, and hypercalcemia has occurred in cancer patients. A case of hepatitis has also been reported.

Toxicology

In an analysis of calcium supplements in Korea, shark cartilage–containing calcium supplements were among the highest in mercury and cadmium content, with levels that could be toxic in pediatric and older adult populations. In another study testing 16 shark cartilage products, 15 of the 16 contained beta-N-methylamino-L-alanine (BMAA), a neurotoxin found in the fins of several species of shark and potentially linked to degenerative brain disease; mercury content was low in these shark fin products. Caution should be used.

History

Shark cartilage is prepared from the cartilage of freshly caught sharks in the Pacific Ocean, predominantly from the spiny dogfish shark (S. acanthias) and the hammerhead shark (S. lewini).(CAM Cancer 2020) One of the main processing plants for dogfish shark is in Costa Rica. The cartilage is cut from the shark, cleaned, shredded, and dried. The finely ground cartilage is uniformly pulverized in a 200 mesh screen, sterilized, and encapsulated. Gelatin capsules contain shark cartilage 740 mg, usually without additives or fillers, and are claimed to be "all natural."(Masslo 1993, Moss 1992) AE-941 received orphan status designation by the US Food and Drug Administration for the treatment of renal cell carcinoma;(Neovastat 2016) however, the use of cartilage as a treatment for people with cancer or any other medical condition has not been approved by the FDA.

Chemistry

Shark cartilage is composed of approximately 40% protein (troponin-I, tetranectin-type protein, collagenase, cartilage-derived inhibitor, and tissue inhibitor of metalloproteinases), 5% to 20% glycosaminoglycans (chondroitin sulfate-D, chondroitin-6-sulfate, keratin sulfate), calcium salts, and glycoproteins (sphyrnastatin-1 and 2, galactosamines, glucosamine).Hammerness 2002 Several studies have been conducted using various shark species. Sphyrnastatins 1 and 2 from the hammerhead shark have been isolated and characterized.Pettit 1977 The isolation of a protein from reef shark (Carcharhinus springeri) cartilage that bears a striking resemblance to human tetranectin was reported.Neame 1992 A broad-spectrum steroidal antibiotic from the dogfish shark has been discovered and named "squalamine"; chemically, it is 3-beta-N-1-(N-[3–(4–aminobutyl)]-1,3-diamino-propane)-7 alpha, 24 zeta-dihydroxy-5 alpha-cholestane 24-sulfate.Moore 1993

Uses and Pharmacology

Anti-inflammatory effects

Shark cartilage may be useful in inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and, in some cases, osteoarthritis. Specifically, it may be beneficial due to its anti-angiogenic effects as well as the presence of high levels of anti-inflammatory mucopolysaccharides such as glucosamine sulfate and chondroitin sulfate. Improvements in inflammation may be noticed as soon as 1 to 2 weeks after initiating treatment with shark cartilage; however, if no improvement occurs, patients should be advised to continue treatment for 6 to 8 weeks before a decision is made to discontinue.(Milner 1999)

Animal and in vitro data

Shark cartilage polysaccharide given to rats at 9 mg/day for 24 days exerted beneficial effects in a model of rheumatoid arthritis (RA). Supplementation reduced paw swelling, inhibited IL-6 and IL-12 secretion, and improved radiologic change of the bone. While shark cartilage was not better than methotrexate on these parameters, the inflammatory process in RA rats without treatment led to increases in levels of the proinflammatory cytokines IL-6 and IL-12.(Chuan-Ying 2012) Similarly, another murine model found that shark cartilage attenuated inflammation when dosed at 3 mg/kg/day orally for 2 weeks.(Chen 2012) However, in an in vitro study, shark cartilage stimulated production of proinflammatory cytokines and chemokines, as well as activated signaling pathways; in vivo, this could lead to exacerbations of inflammatory diseases such as irritable bowel syndrome.(Merly 2015)

Clinical data

A topical combination preparation containing glucosamine sulfate 30 mg/g, chondroitin sulfate 50 mg/g, and shark cartilage 140 mg/g applied for an 8-week period improved visual analog scores for pain compared with placebo at 4 and 8 weeks in patients with osteoarthritis of the knee.(Cohen 2003)

A study examining the role of shark cartilage extract in psoriasis noted anti-inflammatory properties.(Dupont 1998)

Antimicrobial effects

Research has identified the broad-spectrum aminosterol antibiotic squalamine in the dogfish shark. Squalamine has shown bactericidal activity against both gram-negative and gram-positive bacteria. It is also fungicidal and induces activity against protozoa.(Moore 1993) This discovery implicated a unique steroid acting as a potential host-defense agent in vertebrates and provided for a new family of broad-spectrum antibiotics.

Antioxidant effects

In an in vitro study, shark cartilage served as a scavenger against reactive oxygen species and protected cells against inactivation and mutagenesis, suggesting potential antioxidant effects.(Felzenszwalb 1998)

Cancer

There have been many claims regarding the role of shark cartilage as a cure for cancer. The fact that sharks rarely get cancer has led to the theory that because sharks are cartilaginous fish, and cartilage is avascular and contains agents that inhibit vascularization (angiogenesis, promotion of new blood vessels needed for tumor growth and metastasis), the cartilage from sharks can, therefore, cure cancer. The inhibited vascularization theoretically prevents formation of tumors; hence, in humans, use may inhibit tumor angiogenesis and thus possibly cure cancer.(Masslo 1993) Inhibition of angiogenesis through vascular endothelial growth factor and matrix metalloproteinase (MMP), particularly MMP-2, -9, -12, and -13 by shark cartilage extract has been demonstrated.(Jabłońska-Trypuć 2016, Patra 2012, Sauder 2002) It has also induced apoptosis in endothelial cells.(Patra 2012)

Animal and in vitro data

Some of the earliest published data on use of shark cartilage for anticancer effects come from an experimental cornea model in rabbits. Pellets of shark cartilage derived from basking sharks (Cetorhinus maximus) were placed into rabbit corneas, along with V2 carcinoma cells. At 19 days, corneas treated with shark cartilage did not contain any 3-dimensional tumors, unlike the control corneas.(Lee 1983) The study authors suggested that further exploration in experimental models is needed to determine the angiogenesis inhibitory effects of shark cartilage.

An acidic ethanol-precipitate fraction of shark cartilage was associated with reduced incidence and number of adenocarcinomas in the pancreatic ducts of hamsters. Additionally, this fraction inhibited MMP-9.(Kitahashi 2012)

Clinical data

Limited quality clinical studies have been conducted; however, results for some have not been published, (NML_2022) and findings from others are inconclusive.

In a survey of long-term lymphoma survivors (6 to 20 years), 7% (95% confidence interval, 2% to 17%) of patients reported shark cartilage use.(Habermann 2009) In late 1992, incomplete and nonreplicated clinical studies (unpublished) conducted in Havana, Cuba, purported to show some benefit in terminally ill cancer patients. The National Cancer Institute reviewed these studies and decided against researching shark cartilage.(Masslo 1993)

A case report described clinical and histological regression of early-stage cutaneous Kaposi sarcoma in a 45-year-old man positive for human herpesvirus-8 and negative for HIV. Initially, the patient received a 3-month course of ganciclovir with no clinical resolution. Shark cartilage supplementation was then initiated at 3,750 mg divided twice daily for the first 3 months. After 3 months, the Kaposi sarcoma lesion had decreased in size. The dose was increased to 4,500 mg divided 3 times daily for the remainder of the approximately 3-year treatment period.(Hillman 2001) In a phase 2, open-label study of 144 patients with refractory renal cell carcinoma, the effects of shark cartilage extract on survival were assessed. Patients were given either 60 mL/day or 240 mL/day of the extract orally, divided twice daily. Patients treated with the 240 mL/day dose had a longer median survival time (16.3 months) compared with those receiving 60 mL/day (7.1 months; P=0.01).(Batist 2002)

In a 2005 two-armed, randomized, double-blind, placebo-controlled clinical trial in patients with incurable breast or colorectal cancer (N=88), shark cartilage powder was initiated at 24 g and titrated upward as tolerated every 3 days, towards a goal of 96 g given in 3 or 4 divided doses. Results demonstrated no improvement in survival or quality of life (QOL) in patients who received shark cartilage compared with placebo; in fact, QOL variables were confirmed to be significantly worse with shark cartilage supplementation at weeks 2 and 3 (P=0.005 and P=0.05, respectively). For the 24 patients who remained in the study at month 3, QOL, measured using the Symptom Distress Scale, was significantly better in the shark cartilage group (P=0.04), with Linear Analogue Self-Assessment test scores indicating higher emotional and spiritual well-being (P=0.05 and P=0.01, respectively). However, given the very low number of patients in each arm at month 3, results should be interpreted with caution. The most frequent severe toxicities experienced in the shark cartilage group and not observed in the placebo group included diarrhea, dyspnea, leukopenia, neutropenia, and bone pain; most adverse effects were mild to moderate.(Loprinzi 2005)

In a randomized, double-blind, placebo-controlled, phase 3 trial of patients with stage III non–small cell lung cancer treated with chemoradiotherapy, the addition of shark cartilage did not improve overall patient survival compared with placebo. In addition, time to progression, progression-free survival, and tumor response rates were not different between shark cartilage and placebo groups. It should be noted that the study was closed before reaching the targeted sample size due to insufficient accrual of patients.(Lu 2010)

In a study of patients with advanced cancer (breast, colorectal, lung, prostate, non-Hodgkin lymphoma, brain, and unknown tumor), shark cartilage was inactive and had no beneficial effects on QOL.(Miller 1998)

Colonic anastomoses

Following colonic anastomosis in rabbits, administration of shark cartilage increased connective tissue and vascularization without impacting microbial growth or translocation. Bursting pressure (139.29 mm Hg vs 85 mm Hg) and hydroxyproline levels (4.59±0.26 g/mg tissue vs 2.55±0.21 g/mg tissue) were higher in the shark cartilage group compared with controls (P<0.05 for both comparisons). Shark cartilage positively impacted collage synthesis and promoted better vascularization in the anastomosis regions, thereby increasing the strength of the anastomosis.(Sulu 2013)

Fibrinolytic effects

An in vitro study demonstrated that shark cartilage possesses plasmin-independent fibrinolytic activity. Shark cartilage decreased clot firmness; however, there was no impact on clotting time and kinetic parameters.(Ratel 2005)

Immunostimulatory effects

In an in vitro study, a fraction of shark cartilage–derived protein exerted immunostimulatory effects on the cytotoxic activity of natural killer cells.(Bargahi 2011)

Macular degeneration

Due to shark cartilage's antiangiogenic effects, improved or stabilized visual acuity has been reported in a small cohort of patients with macular degeneration.(Hammerness 2002) Additional studies are needed before recommendations can be made regarding the use of shark cartilage in macular degeneration.

Psoriasis

Shark cartilage extract may be beneficial in the management of psoriasis by inhibiting the neovascularization of psoriatic plaques.

Animal and in vitro data

In chick embryos, shark cartilage extract inhibited neovascularization and types 1 and 4 collagenase activity in a concentration-dependent manner.(Dupont 1998)

Clinical data

In a phase 1/2, open-label clinical trial, the effects of shark cartilage extract were assessed in 49 patients with plaque psoriasis. Patients were randomized to receive a regimen of 30, 60, 120, or 240 mL/day extract orally twice daily for 12 weeks, with an additional 12-week follow up period. Only 12 of the 49 patients completed the entire 24-week study. Psoriasis Area and Severity Index (PASI) score improved by 20% or greater in 30.8%, 41.7%, and 50% of patients receiving 60, 120, and 240 mL/day, respectively. Those receiving 30 mL/day did not show an improvement in PASI score.(Sauder 2002) The high withdrawal/dropout rate in this study limits interpretation of the data.

In another study examining the potential role of shark cartilage extract in psoriasis, investigators applied shark cartilage to the ventral forearms, followed by Balsam of Peru, a skin irritant. All doses tested prevented skin irritation, suggesting anti-inflammatory properties.(Dupont 1998)

Uric acid–lowering effects

In a murine model, the basic peptide fraction of shark cartilage was found to exert uric acid–lowering activity.(Murota 2010) At least one of the peptides, Tyr- Leu-Asp-Asn-Tyr, maintains antihyperuricemic activity when administered orally.(Murota 2014)

Dosing

Commercial doses range from 0.5 to 4.5 g/day, given in 2 to 6 divided doses.(CAM Cancer 2020)

Oral shark cartilage preparations should be taken on an empty stomach, and acidic fruit juices should be avoided for 15 to 30 minutes before and after administration.(Hammerness 2002)

Cancer: Studies have evaluated 80 to 100 g/day or 1 to 1.3 g/kg/day of ground extract in 2 to 4 divided doses.(Hammerness 2002) Doses of the shark cartilage derivative AE-941, used in clinical trials, have ranged from 30 to 240 mL/day or 20 mg/kg twice daily.(Hammerness 2002) In patients with incurable breast and colorectal cancer, a powder formulation was initially dosed at 24 g/day and titrated upward every 3 days to a target dose of 96 g/day, administered in divided doses 3 to 4 times a day.(Falardeau 2001)

Joint diseases: 0.2 to 2 g/kg/day in 2 to 3 divided doses have been suggested.(Hammerness 2002)

Psoriasis: 0.4 to 0.5 g/kg/day for 4 weeks, with dosage reduced to 0.2 to 0.3 g/kg/day for 4 additional weeks if skin lesions improve. Topical preparations containing shark cartilage 5% to 30% are also available.(Hammerness 2002)

Pregnancy / Lactation

Avoid use. Information regarding safety and efficacy in pregnancy and lactation is lacking. Although no clinical studies have been conducted, there is a risk of impaired angiogenesis.(CAM Cancer 2020, Hammerness 2002)

Interactions

Coadministration of shark cartilage with other drugs (eg, calcium supplements, thiazide diuretics) may increase calcium levels.(Hammerness 2002)

Alpha-lipoic acid: Calcium salts may decrease the absorption of alpha-lipoic acid. Alpha-lipoic acid may decrease the absorption of calcium salts. Consider therapy modification.(Thioctic September 2014)

Baloxavir marboxil: Polyvalent cation-containing products may decrease the serum concentration of baloxavir marboxil. Avoid combination. This interaction only applies to orally administered polyvalent cation-containing products.(Xofluza October 2018)

Bictegravir: Calcium salts may decrease the serum concentration of bictegravir. Consider therapy modification. This interaction is limited to orally administered calcium salts.(Biktarvy February 2018)

Bisphosphonate derivatives: Polyvalent cation-containing products may decrease the serum concentration of bisphosphonate derivatives. Consider therapy modification. Only oral preparations of bisphosphonate derivatives and oral polyvalent cation containing products are expected to participate in this interaction.(Actonel April 2015, Bonefos September 2011, Boniva April 2015, Didronel April 2015, Fosamax February 2015, Skelid March 2010)

Cabotegravir: Polyvalent cation-containing products may decrease the serum concentration of cabotegravir. Consider therapy modification. This interaction only applies to orally administered cabotegravir and orally administered polyvalent cation containing products.(Vocabria January 2021)

Calcium acetate: Calcium salts may enhance the adverse/toxic effect of calcium acetate. Avoid combination.(PhosLo March 2011)

Calcium channel blockers: Calcium salts may diminish the therapeutic effect of calcium channel blockers. Monitor therapy.(Bar-Or 1981, Haft 1986, O’Quinn 1990, Salerno 1987, Schoen 1991, Wohns 1991)

Cardiac glycosides: Calcium salts may enhance the arrhythmogenic effect of cardiac glycosides. Monitor therapy.(Ejvinsson 1978, Leahey 1978, Nola 1970, Smith 1972, Vella 1999)

Deferiprone: Polyvalent cation-containing products may decrease the serum concentration of Deferiprone. Consider therapy modification. This interaction only applies to orally administered polyvalent cation containing products.(Ferriprox July 2019, Ferriprox April 2018)

Dobutamine: Calcium salts may diminish the therapeutic effect of dobutamine. Monitor therapy. This interaction is likely most clinically significant with IV calcium administration.(Butterworth 1992)

Dolutegravir: Calcium salts may decrease the serum concentration of dolutegravir. Consider therapy modification. This interaction is only anticipated with oral administration of calcium salts.(Federspiel 2021, Juluca November 2017, Tivicay May 2014)

Eltrombopag: Polyvalent cation-containing products may decrease the serum concentration of eltrombopag. Consider therapy modification. This interaction only applies to orally administered polyvalent cation containing products.(Promacta August 2015, Williams 2009)

Elvitegravir: Polyvalent cation-containing products may decrease the serum concentration of elvitegravir. Consider therapy modification. This interaction only applies to orally administered polyvalent cation containing products.(HHS 2020, Genvoya February 2019, Kang-Birken 2019, Ramanathan 2013, Stribild January 2019)

Estramustane: Calcium salts may decrease the absorption of estramustine. Consider therapy modification.(Emcyt 2003, Gunnarsson 1990)

Fluoride: Calcium salts may decrease the serum concentration of fluoride. No action needed. This interaction only applies to ingested fluoride products, but does not apply to topical fluoride products (eg, gels, creams, mouthwashes, pastes).(Flura-Drops September 2019, Spencer 1980)

Lycopene: Calcium salts may decrease the serum concentration of lycopene. No action needed. This interaction only applies to orally administered calcium salts.(Borel 2016)

Moxifloxacin (systemic): Calcium salts may decrease the absorption of moxifloxacin (systemic). No action needed. This interaction only applies to orally administered moxifloxacin and orally administered calcium salts.(Moxifloxacin January 2022, Stass 2001)

Multivitamins/Fluoride (with ADE): Multivitamins/Fluoride (with ADE) may increase the serum concentration of calcium salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Consider therapy modification.(Bjelakovic 2011, EtheDent 2002, Hathcock 2007, Peacock 2010)

Multivitamins/Minerals (with ADEK, folate, iron): Multivitamins/Minerals (with ADEK, folate, iron) may increase the serum concentration of calcium salts. Monitor therapy.(Bjelakovic 2011, Hathcock 2007, Peacock 2010)

PenicillAMINE: Polyvalent cation-containing products may decrease the serum concentration of PenicillAMINE. Consider therapy modification. This interaction only applies to orally administered polyvalent cation containing products.(Brewer 1993, Cuprimine November 2015, Harkness 1982, Lyle 1976, Osman 1983)

Phosphate supplements: Calcium salts may decrease the absorption of phosphate supplements. Consider therapy modification. Only oral preparations of phosphate supplements and calcium salts are expected to participate in this interaction.(Heaney 2002, Lau 1998)

Quinolones: Calcium salts may decrease the absorption of quinolones. Of concern only with oral administration of both agents. Consider therapy modification. Only oral preparations of quinolone antibiotics and calcium salts are expected to participate in this interaction.(Frost 1989, Hoffken 1985, Kays 2003, Lehto 1994, Nix 1990, Sahai 1993, Schentag 1988, Shiba 1992, Shimada 1992, Staff 2001)

Ratelgravir: Polyvalent cation-containing products may decrease the serum concentration of raltegravir. Consider therapy modification. This interaction likely applies only to orally-administered polyvalent cation-containing products.(Bacchi 2011, HHS HIV 2019, HHS Antiretroviral 2019, Isentress May 2017, Moss 2012)

Strontium ranelate: Calcium salts may decrease the serum concentration of strontium ranelate. Consider therapy modification. This interaction applies only to orally administered calcium salts.(Protelos July 2012)

Tetracyclines: Calcium salts may decrease the serum concentration of Tetracyclines. Consider therapy modification. This interaction only applies to concurrent use of oral tetracyclines and oral calcium salts.(Jung 1997, Minocin August 2010, PhosLo March 2011, Tetracycline June 2009, Vibramycin April 2007)

Thiazide and thiazide-like diuretics: Thiazide and thiazide-like diuretics may decrease the excretion of calcium salts. Continued concomitant use can also result in metabolic alkalosis. Monitor therapy.(Drinka 1984, Gora 1989, Hakim 1979, Parfitt 1969)

Thyroid products: Calcium salts may diminish the therapeutic effect of thyroid products. Consider therapy modification.(Butner 2000, Csako 2001, Diskin 2007, Irving 2014, Mazokopakis 2008, Schneyer 1998, Singh 2000, Singh 2001, Zamfirescu 2011)

Trientine: Polyvalent cation-containing products may decrease the serum concentration of trientine. Consider therapy modification. This interaction only applies to orally administered polyvalent cation containing products.(Brewer 1993, Cuvrior April 2022, Syprine December 2016, Walshe 1982)

Vitamin D analogs: Calcium salts may enhance the adverse/toxic effect of vitamin D analogs. Monitor therapy.(Dovonex March 2015, Ergocalciferol October 2018, Fosamax Plus D August 2019, Hectorol November 2018, One-Alpha September 2020, Rayaldee December 2019, Rocalctrol November 1998, Vectical July 2020, Zemplar March 2011)

Adverse Reactions

The most commonly reported adverse effects are mild to moderate and include GI distress and nausea.Hammerness 2002 Taste alterations have also been noted.Batist 2002 Because shark cartilage supplements often contain high levels of calcium (eg, elemental calcium 600 to 780 mg daily), hypercalcemia may occur, particularly in patients with cancer. In 2 case reports of patients with cancer, it was suggested that episodes of symptomatic hypercalcemia were associated with shark cartilage supplementation, especially when used in combination with multivitamins that provide additional calcium and vitamin D.Lagman 2003

A case of immunoglobulin E–mediated allergic occupational asthma has been documented in a 29-year-old man who worked in a dietetic product production facility. Symptoms included chest tightness, cough, and dyspnea that required management with bronchodilators and several hospital admissions. Peak expiratory flow rate decreased by more than 20% during work periods and, along with other symptoms, improved on the weekends and holidays.San-Juan 2004 Another case report described a 38-year-old white man working in a facility that ground shark cartilage. After about 10 months of exposure, he reported dyspnea, coughing, and wheezing, symptoms associated with shark cartilage exposure, and was diagnosed with asthma. Six months later, he reported shortness of breath at work and died; the autopsy report indicated the presence of mucus casts and numerous emphysematous blebs, and confirmed asthma as the cause of death.Ortega 2002 This case is confounded by the patient's smoking history but may be linked to occupational exposure to shark cartilage.

A case report described a 57-year-old man with hepatitis presumed to be induced by shark cartilage. He reported a 3-week history of nausea, vomiting, diarrhea, and anorexia and was found to have elevated liver enzyme, bilirubin, and alkaline phosphatase levels. He had begun taking shark cartilage 10 weeks prior to hospitalization but had reportedly discontinued taking the supplements a few days before his symptoms began due to an odor from the supplements. Six weeks following discharge, he had normal liver function.Ashar 1996

Toxicology

In an analysis of calcium supplements in Korea, shark cartilage–containing calcium supplements were among the highest in mercury and cadmium content, with levels that could be toxic in pediatric and elderly populations.Kim 2004 In another study testing 16 shark cartilage products, 15 of the 16 contained BMAA (a neurotoxin found in the fins of several species of shark and potentially linked to degenerative brain disease) at concentrations ranging from 86 to 265 mcg/g; mercury content was low in these shark fin products.Mondo 2014 Caution should be used.

References

Disclaimer

This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.
Ashar B, Vargo E. Shark cartilage-induced hepatitis. Ann Intern Med. 1996;125(9):780-781.8929024
Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420.220664
Bargahi A, Hassan ZM, Rabbani A, Langroudi L, Noori SH, Safari E. Effect of shark cartilage derived protein on the NK cells activity. Immunopharmacol Immunotoxicol. 2011;33(3):403-409.20670122
Bar-Or D and Gasiel Y. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J. 1981;282(6276):1585-1586.6786574
Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol. 2002;13(8):1259-1263.12181250
Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.
Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011;(7):CD007470.21735411
Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011.
Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.
Borel P, Desmarchelier C, Dumont U, et. al. Dietary calcium impairs tomato lycopene bioavailability in healthy humans. Br J Nutr. 2016;116(12):2091-2096.28069089
Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr. 1993;12(1):26-30.8440814
Butner LE, Fulco PP, Feldman G. Calcium carbonate-induced hypothyroidism. Ann Intern Med. 2000;132(7):595.10744606
Butterworth JF 4th, Zaloga GP, Prielipp RC, Tucker WY Jr, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. Chest. 1992;101(1):174-180.1729065
Chen L, Bao B, Wang N, Xie J, Wu W. Oral administration of shark type II collagen suppresses complete Freund's adjuvant-induced rheumatoid arthritis in rats. Pharmaceuticals (Basel). 2012;5(4):339-352.24281405
Chuan-Ying Y, Lei Z. Effects of shark cartilage polysaccharides on the secretion of IL-6 and IL-12 in rheumatoid arthritis. Pharm Biol. 2012;50(12):1567-1572.22992031
Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee [published correction appears in J Rheumatol. 2003;30(11):2512]. J Rheumatol. 2003;30(3):523-528.12610812
Csako G, McGriff NJ, Rotman-Pikielny P, et al. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother. 2001;35(12):1578-1583.11793625
Cuprimine (penicillamine) [prescribing information]. Bridgewater, NJ: Aton Pharma Inc; November 2015.
Cuvrior (trientine) [prescribing information]. Chicago, IL: Orphalan; April 2022.
Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Update March 6, 2020. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.
Diskin CJ, Stokes TJ, Dansby LM, et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int Urol Nephrol. 2007;39(2):599-602.17216296
Dovonex (calcipotriene) [prescribing information]. Dublin, Ireland: LEO Laboratories Ltd.; March 2015.
Drinka PJ and Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriat Soc. 1984;32(5):405-407.6715769
Dupont E, Savard PE, Jourdain C, et al. Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg. 1998;2(3):146-152.9479080
Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. Br Med J. 1978;1(6108):279-280.620306
Emcyt (estramustine phosphate sodium) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company; 2003.
Ergocalciferol [prescribing information]. Laurelton, NY: Epic Pharma, LLC; October 2018.
EtheDent (sodium fluoride) [prescribing information]. St. Louis, MO: Ethex Corporation; 2002.
Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001;28(6):620-625.11740820
Federspiel J, Bukhari MJ, Hamill MM. Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. BMJ Case Rep. 2021;14(1):e236655.33408101
Felzenszwalb I, Pelielo de Mattos JC, Bernardo-Filho M, Caldeira-de-Araújo A. Shark cartilage-containing preparation: protection against reactive oxygen species. Food Chem Toxicol. 1998;36(12):1079-1084.9862650
Ferriprox (deferiprone) tablets [prescribing information]. Weston, FL: ApoPharma USA Inc; July 2019.
Ferriprox (deferiprone) oral solution [prescribing information]. Weston, FL: ApoPharma USA Inc; April 2018.
Flura-Drops (sodium fluoride) [prescribing information]. Lake Oswego, OR: Kirkman Laboratories Inc; September 2019.
Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck & Co Inc; February 2015.
Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; August 2019.
Frost RW, Lettieri JT, Noe A, et al. Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clin Pharmacol Ther. 1989;45:165.
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2019.
Gora ML, Seth SK, Bay WH, et al. Milk-alkali syndrome associated with use of cholorothiazide and calcium carbonate. Clin Pharm. 1989;8(3):227-229.27006898
Gunnarsson PO, Davidson T, Andersson SB, et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189-193.2338118
Habermann TM, Thompson CA, LaPlant BR, et al. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol. 2009;84(12):795-798.19894247
Haft JI and Habbab MA. Treatment of atrial arrhythmias. Effectiveness of verapamil when preceded by calcium infusion. Arch Intern Med. 1986;146(6):1085-1089.3718093
Hakim R, Tolis G, Goltzman D, et al. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Can Med Assoc J. 1979;121(5):591-594.497950
Hammerness P, Ulbricht C, Barrette EP, et al. Shark cartilage monograph: a clinical decision support tool. J Herb Pharmacother. 2002;2(2):71-93.15277099
Harkness JA, Blake DR. Penicillamine nephropathy and iron. Lancet. 1982;2(8312):1368-1369.6129465
Hathcock JN, Shao A, Vieth R, et al. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85(1):6-18.17209171
Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr. 2002;21(3):239-244.12074251
Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018.
HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. Updated March 17, 2022. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated August 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/AdultandAdolescentGL_2021_08_16.pdf
Hillman JD, Peng AT, Gilliam AC, Remick SC. Treatment of Kaposi sarcoma with oral administration of shark cartilage in a human herpesvirus-8-seropositive, human immunodeficiency virus-seronegative homosexual man. Arch Dermatol. 2001;137(9):1149-1152.11559209
Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4:345.3160584
Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; May 2017.
Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141.25040647
Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(suppl 1):177-183.27028474
Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.
Jung H, Peregrina AA, Rodriguez JM, et al. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm Drug Dispos. 1997;18(5):459-463.9210983
Kang-Birken SL, El-Sayed D, Prichard J. HIV viral rebound due to a possible drug-drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and calcium-containing products: report of 2 cases. J Int Assoc Provid AIDS Care. 2019;18:1-4.30798679
Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42(6):1253-1259.14655198
Kim M. Mercury, cadmium and arsenic contents of calcium dietary supplements. Food Addit Contam. 2004;21(8):763-767.15370826
Kitahashi T, Ikawa S, Sakamoto A, et al. Ingestion of proteoglycan fraction from shark cartilage increases serum inhibitory activity against matrix metalloproteinase-9 and suppresses development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic duct carcinogenesis in hamster. J Agric Food Chem. 2012;60(4):940-945.22225405
Lagman R, Walsh D. Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia. Support Care Cancer. 2003;11(4):232-235.12673461
Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19-22.9554821
Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. JAMA. 1978;240(6):533-534.671662
Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science. 1983;221(4616):1185-1187.6193581
Lehto PL, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482.7955811
Loprinzi CL, Levitt R, Barton DL, et al; North Central Cancer Treatment Group. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer. 2005;104(1):176-182.15912493
Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010;102(12):859-865.20505152
Lyle WH. Penicillamine and iron. Lancet. 1976;2(7982):420.73880
Masslo Anderson J. Biotech Discovers the Shark. MD Magazine. 1993;37:43.
Mazokopakis EE, Giannakopoulos TG, Starakis IK. Interaction between levothyroxine and calcium carbonate. Can Fam Physician. 2008;54(1):39.18208953
Merly L, Smith SL. Pro-inflammatory properties of shark cartilage supplement. Immunopharmacol Immunotoxicol. 2015;37(2):140-147.25600427
Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998;16(11):3649-3655.9817287
Milner M. A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint disease. American Chiropractor. 1999;21:40-42.
Minocin (minocycline) [prescribing information}. Cranford, NJ: Triax Pharmaceuticals, LLC; August 2010.
Mondo K, Broc Glover W, Murch SJ, et al. Environmental neurotoxins β-N-methylamino-L-alanine (BMAA) and mercury in shark cartilage dietary supplements. Food Chem Toxicol. 2014;70:26-32.24755394
Moore KS, Wehrli S, Roder H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA. 1993;90(4):1354-1358.8433993
Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020-3026.22450971
Moss RW. Cancer Therapy: The Independent Consumers Guide to Non-Toxic Treatment & Prevention. New York, NY: Equinox Press; 1992.
Moxifloxacin [prescribing information]. Levittown, PA: Torrent Pharma Inc; January 2022.
Murota I, Tamai T, Baba T, et al. Uric acid lowering effect by ingestion of proteolytic digest of shark cartilage and its basic fraction. J Food Biochem. 2010;34:182-194.
Murota I, Tuguchi S, Sato N, et al. Identification of antihyperuricemic peptides in the proteolytic digest of shark cartilage water extract using in vivo activity-guided fractionation. J Agri Food Chem. 2014;62:2392-2397.
Neame PJ, Young CN, Treep JT. Primary structure of a protein isolated from reef shark (Carcharhinus springeri) cartilage that is similar to the mammalian C-type lectin homolog, tetranectin. Protein Sci. 1992:1(1):161-168.1304877
Neovastat (Ae-941). Orphan Drug Designations and Approvals. U.S. Food and Drug Administration website. Accessed November 21, 2022. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=159202.
Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34:432-435.2334155
Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79(4):499-507.5418023
O’Quinn SV, et al. Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing. Pharmacotherapy. 1990;10:247 [abstract].
One-Alpha drops (alfacalcidol) [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020.
Ortega HG, Kreiss K, Schill DP, Weissman DN. Fatal asthma from powdering shark cartilage and review of fatal occupational asthma literature. Am J Ind Med. 2002;42(1):50-54.12111690
Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulphate. Clin Pharmacol Ther. 1983;33(4):465-470.6831825
Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969;281(2):55-59.5305802
Patra D, Sandell LJ. Antiangiogenic and anticancer molecules in cartilage. Expert Rev Mol Med. 2012;14:e10.22559283
Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010(5 Suppl 1):s23-s30.20089499
Pettit GR, Ode RH. Antineoplastic agents L: isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark Sphyrna lewini. J Pharm Sci. 1977;66(5):757-758.874772
PhosLo (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; March 2011.
Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015.
Protelos (strontium ranelate) [prescribing information]. Gidy, France: Les Laboratoires Servier Industrie, July 2012.
Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64(1):45-50.23774876
Ratel D, Glazier G, Provençal M, et al. Direct-acting fibrinolytic enzymes in shark cartilage extract: potential therapeutic role in vascular disorders. Thromb Res. 2005;115(1-2):143-152.15567466
Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019.
Rocalctrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998.
Sahai J, Healey DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302-304.8471407
Salerno DM, Anderson B, Sharkey PH, et al. Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment. Ann Intern Med. 1987;107(5):623-628.3662276
San-Juan S, Garcés M, Caballero ML, Monzón S, Moneo I. Occupational asthma caused by shark cartilage dust. J Allergy Clin Immunol. 2004;114(5):1227-1228.15536437
Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol. 2002;47(4):535-541.12271297
Schentag JJ, Watson WA, Nix DE, et al. Time-dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol Ther. 1988;43:135.
Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA. 1998;279(10):750.9508149
Schoen MD, Parker RB, Hoon TJ, et al. Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects. Am J Cardiol. 1991;67(4):300-304.1990794
Complementary and Alternative Medicine for Cancer. Shark Cartilage. Updated September 15, 2020. Accessed July 20, 2022. https://cam-cancer.org/en/shark-cartilage.
Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulphate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36:2270-2274.1444308
Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36:1219-1234.1329615
Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283:2822-2825.10838651
Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001;11:967-971.11716045
Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010.5062119
Smith RB, Petruscak J. Succinylcholine, digitalis, and hypercalcemia: a case report. Anesth Analg. 1972;51(2):202-205.
Spencer H, Kramer L, Osis D, Wiatrowski E, Norris C, Lender M. Effect of calcium, phosphorus, magnesium, and aluminum on fluoride metabolism in man. Ann N Y Acad Sci. 1980;355:181-194.6940475
Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32.11352439
Stass H, Wandel C, Delesen H, Moller JG. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(suppl 1):27-32.11352439
Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2019.
Sulu B, Cihan M, Gunerhan Y, Sozmen M. The healing effect of shark cartilage in rabbits after colonic anastomosis. Ann Ital Chir. 2013;84(3):351-356.23857288
Syprine (trientine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016
Tetracycline [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; June 2009.
Thioctic acid tablet [KR prescribing information]. Available at https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200201478. Accessed September 1, 2014.
Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014.
Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999;75(887):554-556.10616693
Vectical (calcitriol) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020.
Vibramycin (doxycycline) [prescribing information]. New York, NY: Pfizer Inc, April 2007.
Vocabria (cabotegravir) tablets [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; January 2021.
Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1(8273):643-647.6121964
Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764-776.19446149
Wohns DH, Patterson JH, Clarke S, et al. Influence of calcium administration on the short-term hemodynamic and the anti-ischemic effects of nifedipine. J Am Coll Cardiol. 1991;18(4):1070-1076.1894852
Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; October 2018.
Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-486.21595516
Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright © 2024 Wolters Kluwer Health